Primary liver cancers present major diagnostic challenges for clinicians globally. Specifically, differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma (IMCC) is clinically difficult due to overlapping imaging features. Therefore, a multi-center study evaluated a new diagnostic model to address this issue. This model combines specific gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI features with serum biomarkers. Consequently, this approach may help clinicians guide therapeutic decisions in chronic hepatitis B virus (HBV) patients.
Key Challenges in Scirrhous Hepatocellular Carcinoma
Differentiating these two malignancies is critical. However, standard imaging often fails because both tumors contain rich fibrous stroma. As a result, both lesions frequently display atypical enhancement patterns. Furthermore, standard MRI struggles to provide clear differentiation without advanced contrast agents. Thus, misdiagnosis can lead to inappropriate treatment selection, impacting patient survival rates. To solve this, researchers retrospectively analyzed 183 patients with pathologically confirmed tumors.
Developing the Diagnostic Model
The study cohort included 63 patients with scirrhous hepatocellular carcinoma and 120 patients with IMCC. Initially, researchers used data from 118 patients at one center for training. Subsequently, they validated the findings using data from 65 patients across two other centers. During the analysis, the team identified several independent diagnostic factors. Specifically, non-thin rim arterial enhancement, an enhancing capsule, and T1 opposed-phase signal loss proved highly predictive. Additionally, the researchers incorporated relevant serum biomarkers to improve accuracy.
Impressive Accuracy and Clinical Benefits
Overall, the integrated diagnostic model demonstrated exceptional performance. In the training phase, the model achieved an area under the curve (AUC) of 0.951. Moreover, the model showed a high sensitivity of 85.9% and a specificity of 88.4%. During external validation, the model maintained an AUC of 0.939. Consequently, these results confirm the high reliability of the approach. Furthermore, decision curve analysis demonstrated positive clinical utility. This model can help clinicians tailor highly personalized treatment strategies and improve patient prognoses in India.
Frequently Asked Questions
Q1: What is the primary clinical challenge in differentiating SHCC from IMCC?
Specifically, both tumors are aggressive liver cancers that often show overlapping features, making accurate pre-operative diagnosis difficult.
Q2: Which Gd-EOB-DTPA MRI features help identify scirrhous hepatocellular carcinoma?
In particular, key features include non-thin rim arterial enhancement, an enhancing capsule, and opposed-phase T1-weighted signal loss.
Q3: How well does the preoperative diagnostic model perform?
Indeed, the combined model achieved an outstanding AUC of 0.951 in training and 0.939 during external validation.
References
- He H et al. Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study. Eur Radiol. 2026 Jul 20. doi: 10.1007/s00330-026-12749-4. PMID: 42477119.
- Chong YS et al. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol. 2012;67(11):1035-1042.
- Choi JY et al. Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review. AJR Am J Roentgenol. 2022;218(3):402-411.